Japanese Encephalitis News and Research

RSS
Japanese encephalitis (previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito ''Culex tritaeniorhynchus''. This disease is most prevalent in Southeast Asia and the Far East.
Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech announces the pricing for ROTAVAC vaccine

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac reports fourth quarter net sales of $9.1 million

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

ITMNs can reduce Japanese Encephalitis transmission to humans

ITMNs can reduce Japanese Encephalitis transmission to humans

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Intercell reports EUR 255.2m net loss for full year 2010

Intercell reports EUR 255.2m net loss for full year 2010

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Global Health Consortium to support development of vaccines to control dengue fever

Global Health Consortium to support development of vaccines to control dengue fever

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen completes memorandum of understanding with Duke-NUS

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac third quarter sales decrease 7% to $9.6 million

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Intercell reports significant increase in second quarter revenue

Intercell reports significant increase in second quarter revenue